We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA: Drugmakers Should Take Lifecycle Approach to Analytical Methods Validation
FDA: Drugmakers Should Take Lifecycle Approach to Analytical Methods Validation
Drugmakers making changes to analytical validation methods over the lifecycle of a drug should retain samples to permit comparative studies of the new and old methods, the FDA says.